Johnson & Johnson (NYSE: JNJ) reported fourth quarter 2023 earnings results today. Reported sales increased 7.3% year-over-year to $21.4 billion. Net earnings
Search Results for: Johnson & Johnson
Johnson & Johnson (JNJ) set to report Q4 earnings. Here’s what to expect
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) will be publishing fourth-quarter results next week. Over the years, the company has enjoyed an
Johnson & Johnson (JNJ) focuses on innovation after separating consumer business
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) recently raised its full-year guidance to reflect the strong performance of the pharmaceutical and medical
JNJ Earnings: All you need to know about Johnson & Johnson’s Q3 2023 earnings results
Johnson & Johnson (NYSE: JNJ) reported third quarter 2023 earnings results today. Reported sales increased 6.8% year-over-year to $21.3 billion. Operational sales
Johnson & Johnson to report earnings on Oct 17. Here’s what to look for
After reporting better-than-expected quarterly earnings consistently for over a decade, healthcare behemoth Johnson & Johnson (NYSE: JNJ) is preparing to release its
Johnson & Johnson (JNJ) Q2 2023 Earnings: Key financials and quarterly highlights
Johnson & Johnson (NYSE: JNJ) reported second quarter 2023 earnings results today. Reported sales increased 6.3% year-over-year to $25.5 billion. GAAP net
Earnings Preview: Here’s what to expect from Johnson & Johnson’s Q2
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) entered a new phase recently after spinning off its consumer business. The move is part
JNJ Earnings: All you need to know about Johnson & Johnson’s Q1 2023 earnings results
Johnson & Johnson (NYSE: JNJ) reported its first quarter 2023 earnings results today. Reported sales increased 5.6% year-over-year to $24.7 billion. On a
JNJ Earnings: All you need to know about Johnson & Johnson’s Q4 2022 earnings results
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2022 earnings results today. Reported sales decreased 4.4% year-over-year to $23.7 billion. Net
JNJ Earnings: Johnson & Johnson Q3 adj. profit drops despite higher sales
Johnson & Johnson (NYSE: JNJ) reported a decline in adjusted profit for the third quarter of 2022, despite a modest increase in net
Johnson & Johnson (JNJ) offers long-term stability. Is the stock a buy?
Johnson & Johnson (NYSE: JNJ) has stayed largely unaffected by the COVID crisis and macroeconomic headwinds so far, which allowed the healthcare
JNJ Earnings: Johnson & Johnson reports higher sales and adj. profit for Q2
Johnson & Johnson (NYSE: JNJ) reported an increase in sales and adjusted profit for the second quarter of 2022 when strong performance by
What awaits Johnson & Johnson (JNJ) beyond consumer business spinoff
Johnson & Johnson (NYSE: JNJ) is probably the most diversified healthcare firm that owns several popular consumer brands, which have brought both
Johnson & Johnson (JNJ) reports Q1 2022 earnings
Johnson & Johnson (NYSE: JNJ) reported first-quarter 2022 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue
Johnson & Johnson (JNJ) reports Q4 2021 earnings
Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2021 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue
Johnson & Johnson (JNJ) reports Q3 2021 earnings
Johnson & Johnson (NYSE: JNJ) reported third-quarter 2021 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue
Johnson & Johnson (JNJ) Q2 2021 Earnings Call
Johnson & Johnson (NYSE: JNJ) Q2 2021 earnings call dated Jul. 21, 2021 Corporate Participants: Christopher DelOrefice — Vice President, Investor Relations Joseph J. Wolk — Executive
Johnson & Johnson beats in Q2; raises FY guidance
Johnson & Johnson (NYSE: JNJ) reported second-quarter 2021 financial results before the regular market hours on Wednesday. The pharmaceutical giant reported Q2
Johnson & Johnson (JNJ) Q1 2021 Earnings Call
Johnson & Johnson (NYSE: JNJ) Q1 2021 earnings call dated Apr. 20, 2021 Corporate Participants: Christopher DelOrefice — Vice President of Investor Relations Joseph J. Wolk — Executive Vice
Johnson & Johnson’s (JNJ) single-dose vaccine is effective but lags behind rivals
Johnson & Johnson (NYSE: JNJ) is the latest pharma company to provide results from the trial of its COVID-19 vaccine candidate. The company
Johnson & Johnson (JNJ): Strength in ecommerce drives growth in Consumer Health
Shares of Johnson & Johnson (NYSE: JNJ) gained nearly 3% in morning trade on Tuesday after the company reported fourth quarter 2020